U.S. Capital Markets Stock News

Earlier in January 2026, Ocugen announced positive preliminary 12‑month Phase 2 ArMaDa data for OCU410 in geographic atrophy secondary to dry age‑related macular degeneration, showing reduced lesion growth and favorable safety across evaluated patients. An interesting highlight is that medium doses produced greater lesion growth reduction than high doses, and no serious OCU410‑related adverse events were reported in either Phase 1 or Phase 2 so far. Next, we’ll assess how this early OCU410...

AvalonBay Communities, NYSE:AVB, has released the final tax treatment classification for its 2025 dividend distributions. The update details how different portions of the 2025 dividends will be categorized for tax purposes under current regulations. The announcement gives existing and prospective shareholders clearer information for tax planning around AVB’s upcoming payouts. AvalonBay Communities, NYSE:AVB, is putting hard numbers around its 2025 dividend tax classifications at a time...

3M (MMM) has wrapped up FY 2025 with fourth quarter revenue of US$6.1b and basic EPS of US$1.08, alongside trailing 12 month revenue of US$24.9b and EPS of US$6.05 that frame how the latest results sit in a broader earnings picture. The company has seen quarterly revenue move from US$6.0b in Q4 2024 to US$6.1b in Q4 2025, while basic EPS shifted from US$1.34 to US$1.08 over the same period, setting a mixed backdrop for any discussion of earnings quality and momentum. With trailing net profit...

NCR Atleos (NYSE:NATL) has partnered with Epirus Bank in Greece to modernize the bank's ATM network. The agreement introduces a branded ATM as a Service model using the Atleos platform and Cashzone network. The partnership is intended to expand cash access and improve self-service banking for Epirus Bank customers across Greece. NCR Atleos focuses on self-service banking technology and ATM outsourcing, and this new agreement with Epirus Bank provides another data point on how its ATMaaS...

Ross Stores (NasdaqGS:ROST) is reporting strong same store sales growth, reflecting solid demand for its off price offering. The company has completed a CEO transition while maintaining operational momentum. Management is continuing with an aggressive store expansion program across its footprint. Ross Stores, trading at $189.69, has seen its shares rise 28.8% over the past year and 79.6% over the past five years. Over the past three years, the stock is up 66.5%, while year to date it is up...

Jefferies has upgraded Ramaco Resources (NasdaqGS:METC) from Hold to Buy. The upgrade is linked to potential upside in metallurgical coal prices. Jefferies also points to positive sentiment around Ramaco's Brook Mine rare earth project. Geopolitical developments are a key part of the thesis behind the new rating. Ramaco Resources is a producer of metallurgical coal used primarily in steelmaking. Any shift in coal pricing can quickly change how investors view the stock. The new rating from...

EnerSys (NYSE:ENS) has seen a sharp rise in its share price over the past six months. The stock move comes alongside reports of declining unit sales over the last two years. Revenue growth forecasts are described as modest, with gross margins remaining low. Investors are weighing strong quarterly results against these underlying business challenges. EnerSys, a supplier of energy storage and related solutions, now sits in a spotlight that is as much about its operations as its stock chart...

BofA Securities upgraded Magnolia Oil & Gas (NYSE:MGY) to Buy, citing strong operational performance. The call highlights resilience in a challenging commodity price environment and recent production results at key oil fields. Several institutions have issued positive commentary on Magnolia Oil & Gas, pointing to its balance sheet and development plans. Magnolia Oil & Gas focuses on oil and gas production, with core assets that have drawn fresh attention after recent field results. For you...

Fastenal (FAST) just wrapped up FY 2025 with fourth quarter revenue of US$2.0b and EPS of US$0.26, capping a trailing twelve month run that produced US$8.2b in revenue and EPS of US$1.10. Over the past year, the company has seen revenue move from US$7.5b to US$8.2b and EPS edge from about US$1.00 to US$1.10, while net income on a trailing basis has tracked around US$1.2b. With net profit margins holding in the mid-teens, investors now have a clearer view of how consistent profitability and...

Comerica (CMA) just wrapped up FY 2025 with fourth quarter revenue of US$836 million and basic EPS of US$1.28, supported by trailing twelve month revenue of US$3.27 billion and EPS of US$5.33. Over recent periods, the bank has seen revenue move from US$3.20 billion and EPS of US$5.05 in the twelve months to Q4 2024 to US$3.27 billion and EPS of US$5.33 in the latest twelve month stretch, giving investors a clearer read on how earnings and top line are tracking together. With a trailing net...

Earlier this month, Calumet, Inc. announced that Calumet Specialty Products Partners, L.P. and Calumet Finance Corp. completed an upsized private placement of US$405 million in 9.75% Senior Notes due 2031 under Rule 144A and Regulation S, issuing the notes at 98.996% of par for net proceeds of about US$393 million. The company plans to use the proceeds, alongside cash on hand and its revolving credit facility, to redeem its higher-coupon 11.00% 2026 and 8.125% 2027 senior notes, potentially...

F.N.B (FNB) is back in the spotlight today as the regional bank prepares to report quarterly earnings, with investors focused on whether its recent revenue momentum and steady analyst expectations hold up. See our latest analysis for F.N.B. At a share price of $17.27, F.N.B has seen a 12.8% 90 day share price return and an 11.9% 1 year total shareholder return, suggesting momentum has been building ahead of the upcoming earnings update and recent analyst coverage. If F.N.B’s setup has your...

Forestar Group (FOR) opened fiscal 2026 with Q1 revenue of US$273 million and basic EPS of US$0.30, setting a measured tone after a very strong finish to 2025. The company has seen quarterly revenue move from US$250.4 million in Q1 2025 to US$551.4 million in Q4 2024 and then US$670.5 million in Q4 2025. Over the same periods, basic EPS ran from US$0.32 to US$1.61 and then US$1.71, so the latest print lands against a backdrop of high recent throughput and puts the focus firmly on how margins...

Richtech Robotics FY 2025 Earnings Snapshot Richtech Robotics (RR) closed FY 2025 with Q4 revenue of US$1.4 million and a basic EPS loss of US$0.02, as net income excluding extra items came in at a loss of US$3.6 million. This result sets the stage for another year of rebuilding the path toward profitability. The company reported quarterly revenue moving from US$1.3 million in Q1 2025 to US$1.4 million in Q4 2025, while basic EPS ranged between a loss of US$0.04 and a loss of US$0.02 across...

Wondering if Kaspi.kz at US$77.40 is offering real value or just headline noise? This article walks through what the current price could mean for you as an investor. The share price closed at US$77.40, with a 1.3% decline over the last 7 days, a 0.2% decline over the last 30 days, a 0.2% decline year to date, a 19.0% decline over 1 year, and returns of 17.8% over 3 years and 53.6% over 5 years. Recent coverage of Kaspi.kz has focused on how the business fits into the broader fintech and...

U.S. Bancorp (USB) just posted another solid update, with third quarter FY 2025 revenue at US$6.7b and EPS at US$1.22, giving investors a clear look at the bank's current earnings power. Over recent quarters, revenue has moved from US$6.3b in Q3 FY 2024 to US$6.4b in Q4 FY 2024 and then to US$6.7b in Q3 FY 2025, while quarterly EPS has ranged from about US$1.01 to US$1.22 across that same stretch. With net income holding in the US$1.6b to US$1.9b range and profitability supported by metrics...

KeyCorp (KEY) just posted another solid quarter, with Q3 FY 2025 revenue at US$1,779 million and basic EPS of US$0.41, while trailing twelve month revenue sat at US$5,934 million and EPS at US$0.87. Over the past few reporting periods, revenue has moved from US$816 million in Q4 2024 to US$1,646 million in Q1 2025, US$1,693 million in Q2 2025 and now US$1,779 million in Q3 2025. Quarterly EPS has shifted from a loss of US$0.28 in Q4 2024 to US$0.34, US$0.35 and US$0.41 respectively. With that...

Ascendis Pharma (NasdaqGS:ASND) reported positive topline Week 52 results from its COACH Phase 2 trial in children with achondroplasia. The combination therapy showed durable growth, improved body proportionality, and a favorable safety profile over the 52 week period. The data support the company’s achondroplasia program as a potential backbone treatment approach for pediatric patients. Ascendis Pharma, a biopharmaceutical company focused on endocrinology related rare diseases, is...

Peoples Bancorp (PEBO) has put up a solid set of headline numbers for FY 2025 Q3, with total revenue of US$107.9 million, basic EPS of US$0.83 and net income of US$29.2 million, while its net profit margin over the last twelve months sits at 18.2% compared with 24.6% a year earlier. Over recent quarters the company has seen revenue move from US$106.97 million in FY 2024 Q3 to US$97.82 million in FY 2025 Q2 and then to US$107.9 million in FY 2025 Q3, alongside quarterly EPS prints of US$0.90,...

Mercantile Bank (MBWM) just posted its FY 2025 third quarter numbers with total revenue of US$62.2 million and basic EPS of US$1.46, alongside net income, excluding extra items, of US$23.8 million, giving investors a clean read on core profitability. The bank has seen revenue move from US$56.9 million in Q3 2024 to US$62.2 million in Q3 2025, while quarterly EPS has shifted from about US$1.22 to US$1.46 over the same period. Trailing twelve month EPS is roughly US$5.28, and investors are...

In January 2026, Castle Biosciences reported that 2025 total revenue is expected to exceed US$340 million, above its prior US$327–US$335 million range, alongside strong year-on-year growth in test volumes for its core DecisionDx-Melanoma and TissueCypher Barrett’s Esophagus assays. The sharp increase in core test reports, particularly for TissueCypher, suggests that Castle’s efforts to broaden clinical adoption and utilization are gaining traction across its key diagnostic franchises. Now...

It's not a stretch to say that Kingsoft Cloud Holdings Limited's ( NASDAQ:KC ) price-to-sales (or "P/S") ratio of 2.8x...

The market was pleased with the recent earnings report from The Simply Good Foods Company ( NASDAQ:SMPL ), despite the...

Key Insights Scotts Miracle-Gro's Annual General Meeting to take place on 26th of January Total pay for CEO Jim...